Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
NCT06436248
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The overall goal of the Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer (PROMISE) study is to better understand how women may incorporate both polygenic risk score (PRS) and novel early detection strategies in their decisions regarding cancer screening and risk reducing surgery. This study will conduct qualitative interviews to better understand women's attitudes regarding polygenic risk score (PRS) and early detection assays.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Cancer
- BRCA Mutation
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 25 years and older
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Last updated on ClinicalTrials.gov
- October 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- Abramson Cancer Center · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.